Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
atropine sulfate + metaproterenol
- Development stage
- Unknown
- Modality
- Small Molecules
- Administration
- Inhalation
01
Overview
Atropine sulfate + metaproterenol is a combination medication used in the treatment of acute asthma. Atropine sulfate is a muscarinic antagonist that blocks severe or life-threatening muscarinic effects, while metaproterenol is a bronchodilator. Clinical data suggests that nebulized atropine sulfate yields no additional bronchodilation during a 2-hour observation period when added initially to metaproterenol in the treatment of acute asthma.
02
Targets
mAChR (Muscarinic acetylcholine receptors)ADRB2 (β2)
Beyond the preview
Go deeper on atropine sulfate + metaproterenol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on atropine sulfate + metaproterenol.